Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Merck shortage of BCG
View:
Post by paddler1 on Feb 15, 2023 4:47pm

Merck shortage of BCG

https://www.cnn.com/2023/02/15/health/cancer-drug-shortage-bcg/index.html
Comment by Longholder99 on Feb 15, 2023 5:09pm
"The BCG shortage is expected to go on for years"......
Comment by CAinPlap on Feb 15, 2023 6:09pm
In light of the fact that the current standard of care cannot be administered properly due to the shortage of BCG, one could argue that TLT should be considered for approval for more than just BCG unresponsive. Given our safety profile and our impressive results to date, I cannot see how we don't get approved. I will lose what little faith I have in the beauracracy that is the FDA if we don ...more  
Comment by Paradise818 on Feb 15, 2023 7:03pm
Agree.  If TLT doesn't get approved based on all of the clinical data, I would conclude that the FDA is one of the most corrupt organization ever.  This is based on current and prior history.  I hope that the results are so overwhelming that they will have no choice but they have done it before.
Comment by charlierock on Feb 15, 2023 8:00pm
Corruption by the FDA in regards to holding back TLT has been the topic of discussion here from time to time but ask yourself this. If there was something sinister going on behind the scenes then why would the FDA have granted us FAST TRACK DESIGNATION? Why would they be in frequently communication with our company concerning trials? 
Comment by Paradise818 on Feb 15, 2023 9:12pm
Not saying that there is anything sinister going on behind the scene but giving that the FDA is part of Big Pharma, I wouldn't be suprise if it is.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250